Choose a Topic
- All Topics
- ASH 2017
- AML
- MDS
- Lymphomas and CLL
- Older Patient HCT
- Sickle Cell Disease
- Post-Transplant
- GVHD
- Patient Eligibility
- CIBMTR Publications
- Cord Blood
- Pediatric HCT
- ALL
- CML
- Multiple Myeloma
- Neuroblastoma
- Non-Malignant Disorders
- HLA Matching
- Preparative Regimens
- BMT CTN Publications
- Unrelated Donor HCT
- ASH 2018
- ASH 2020
Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Gooptu M, et al., Blood—An observational study from the CIBMTR Graft Sources Working Committee found that 8/8 matched unrelated donor hematopoietic cell transplantation (HCT) with PTCy based graft versus host disease (GVHD) prophylaxis resulted in superior overall survival and disease-free survival compared to haploidentical HCT with PTCy in the reduced intensity conditioning (RIC) setting for treatment of acute leukemia and myelodysplastic syndromes. It is the first known study that offers a direct comparison between the two donor sources using PTCy.